Biotts, in collaboration with Bioton S.A., has achieved a historic milestone by successfully delivering insulin through a transdermal patch, eliminating the need for injections.
Key highlights from the media coverage include:
- Stable Concentration Levels: The bioavailability of transdermal insulin at 55%, offering a more stable and consistent therapeutic effect.
- Prolonged Insulin Effectiveness: Insights on how our transdermal patch keeps insulin active in the bloodstream for up to five days, compared to less than one day for injections.
- Reduced Injection Frequency: Details on how patients with Type 1 diabetes could replace up to 20 injections with a single patch worn for a few hours.
- Enhanced Patient Comfort: Benefits such as improved comfort and reduced medical waste, making diabetes management more convenient and less invasive.
This innovation promises to improve patient comfort and care, making diabetes management more convenient and less invasive. The next phase aims to bring this technology to market by 2027, offering a viable alternative to traditional insulin injections.
You can read the full article here.